Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:52 PM
Ignite Modification Date:
2025-12-24 @ 10:52 PM
NCT ID:
NCT02626169
Eligibility Criteria:
Inclusion Criteria:
Provision of informed consent prior to any study specific procedures
Women of childbearing potential must be using an acceptable method of contraception to avoid pregnancy throughout the study
Patients with stable coronary artery disease (3-12 months after Acute Coronary Syndrome) who receive clopidogrel for at least 3 months.
Exclusion Criteria:
Recent stroke or acute coronary syndromes (\<3 months before randomization).
Concurrent use of aspirin \>100 mg/day where the dose reduction to 81 mg/day is contraindicated.
Current use of theophylline.
Concurrent use of Non Steroidal Anti-Inflammatory Drugs.
Patients receiving the following medications: ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, telithromycin, rifampin, dexamethasone, phenytoin, carbamazepine, or phenobarbital. Patients receiving simvastatin or lovastatin at doses greater than 40 mg daily.
Patients with type 2 diabetes with a fasting plasma glucose greater than 200 mg/dl.
Active inflammatory disease or chronic infection.
Contraindication for aspirin, clopidogrel or ticagrelor.
Women who are pregnant or breastfeeding.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT02626169
Study Brief:
Protocol Section:
NCT02626169